AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	4203	127-09-3

Description:

Molecule	Description
Synonyms: sodium acetate anhydrous sodium acetate acetic acid, sodium salt sodium acetate anhydrous	The trihydrate sodium salt of acetic acid, which is used as a source of sodium ions in solutions for dialysis and as a systemic and urinary alkalizer, diuretic, and expectorant. Molecular weight: 82.03 Formula: C2H3NaO2 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

sodium acetate
anhydrous sodium acetate
acetic acid, sodium salt
sodium acetate anhydrous

The trihydrate sodium salt of acetic acid, which is used as a source of sodium ions in solutions for dialysis and as a systemic and urinary alkalizer, diuretic, and expectorant.

Molecular weight: 82.03
Formula: C2H3NaO2
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
May 4, 1983	FDA	HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic anterior segment syndrome	524.08	70.28	69	480	2181	90625717
Endophthalmitis	229.70	70.28	37	512	4648	90623250
Post procedural complication	88.81	70.28	21	528	19021	90608877
Anterior chamber inflammation	72.86	70.28	10	539	410	90627488

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic anterior segment syndrome	417.48	35.15	61	690	1355	42619229
Endophthalmitis	125.53	35.15	26	725	4407	42616177
Cataract operation complication	76.71	35.15	10	741	88	42620496
Post procedural complication	70.52	35.15	20	731	12570	42608014
Keratitis	47.68	35.15	10	741	1781	42618803

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic anterior segment syndrome	806.43	37.46	114	1081	3340	110584764
Endophthalmitis	326.22	37.46	59	1136	8128	110579976
Post procedural complication	138.64	37.46	36	1159	26622	110561482
Cataract operation complication	129.60	37.46	17	1178	268	110587836
Anterior chamber disorder	50.70	37.46	7	1188	164	110587940
Keratitis	47.27	37.46	11	1184	5133	110582971
Corneal oedema	41.20	37.46	9	1186	3164	110584940
Intraocular pressure increased	39.10	37.46	11	1184	10865	110577239

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B05XA08	BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS I.V. SOLUTION ADDITIVES Electrolyte solutions
CHEBI has role	CHEBI:35610	antineoplastic agent

Related Drugs by ATC class:

B05XA Electrolyte solutions 18 drugs

ammonium chloride calcium chloride calcium gluconate hydrochloric acid magnesium chloride magnesium phosphate magnesium sulfate potassium acetate potassium chloride potassium lactate potassium phosphate sodium bicarbonate show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Anuria	contraindication	2472002	DOID:2983
Classical phenylketonuria	contraindication	7573000
Poisoning by digitalis glycoside	contraindication	12876009
Hyperkalemia	contraindication	14140009
Complete atrioventricular block	contraindication	27885002
Sarcoidosis	contraindication	31541009	DOID:11335
End stage renal disease	contraindication	46177005	DOID:784
Humoral hypercalcemia of malignancy	contraindication	47709007
Heart disease	contraindication	56265001	DOID:114
Congenital myotonia, autosomal dominant form	contraindication	57938005
Acute nephropathy	contraindication	58574008
Hypercalcemia	contraindication	66931009	DOID:12678
Ventricular fibrillation	contraindication	71908006
Hypercalciuria	contraindication	71938000
Hyperchloremia	contraindication	74450001
Third degree burn injury	contraindication	80247002
Oliguria	contraindication	83128009
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Hyporeninemic hypoaldosteronism	contraindication	236464008
Familial hyperkalemic periodic paralysis	contraindication	304737009	DOID:14451
Azotemia	contraindication	445009001
Severe dehydration	contraindication	450316000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN		Ki	4.97		CHEMBL
Carbonic anhydrase	Enzyme		CAN_CANAL		Ki	4.44		CHEMBL

External reference:

ID	Source
4017442	VUID
N0000145830	NUI
6131-90-4	SECONDARY_CAS_RN
4017442	VANDF
4018697	VANDF
C0142785	UMLSCUI
CHEBI:32954	CHEBI
CHEMBL1354	ChEMBL_ID
D019346	MESH_DESCRIPTOR_UI
DB09395	DRUGBANK_ID
4550K0SC9B	UNII
517045	PUBCHEM_CID
267453	RXNORM
1707	MMSL
5468	MMSL
72037	MMSL
NOCODE	MMSL
d00471	MMSL
000744	NDDF
000756	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-0795	SOLUTION	3.90 mg	OPHTHALMIC	NDA	9 sections
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-0795	SOLUTION	3.90 mg	OPHTHALMIC	NDA	9 sections
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-1795	SOLUTION	3.90 mg	OPHTHALMIC	NDA	9 sections
Balanced Salt	HUMAN PRESCRIPTION DRUG LABEL	6	0264-1945	SOLUTION	3.90 mg	IRRIGATION	ANDA	11 sections
Physiolyte	HUMAN PRESCRIPTION DRUG LABEL	5	0264-2205	IRRIGANT	0.37 g	IRRIGATION	NDA	20 sections
Physiolyte	HUMAN PRESCRIPTION DRUG LABEL	5	0264-2205	IRRIGANT	0.37 g	IRRIGATION	NDA	20 sections
Isolyte S	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7703	INJECTION, SOLUTION	0.37 g	INTRAVENOUS	NDA	19 sections
Isolyte S	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7703	INJECTION, SOLUTION	0.37 g	INTRAVENOUS	NDA	19 sections
Isolyte S pH 7.4	HUMAN PRESCRIPTION DRUG LABEL	7	0264-7707	INJECTION, SOLUTION	0.37 g	INTRAVENOUS	NDA	24 sections
Isolyte S pH 7.4	HUMAN PRESCRIPTION DRUG LABEL	7	0264-7707	INJECTION, SOLUTION	0.37 g	INTRAVENOUS	NDA	24 sections
Isolyte P in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7730	INJECTION, SOLUTION	0.32 g	INTRAVENOUS	NDA	23 sections
Isolyte P in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7730	INJECTION, SOLUTION	0.32 g	INTRAVENOUS	NDA	23 sections
Plasma-Lyte A	HUMAN PRESCRIPTION DRUG LABEL	5	0338-0221	INJECTION, SOLUTION	368 mg	INTRAVENOUS	NDA	19 sections
Plasma-Lyte A	HUMAN PRESCRIPTION DRUG LABEL	5	0338-0221	INJECTION, SOLUTION	368 mg	INTRAVENOUS	NDA	19 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1113	INJECTION	297 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1113	INJECTION	297 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1115	INJECTION	297 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1115	INJECTION	297 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1123	INJECTION	340 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1123	INJECTION	340 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1125	INJECTION	340 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1125	INJECTION	340 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1142	INJECTION	217 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1142	INJECTION	217 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1144	INJECTION	297 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1144	INJECTION	297 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1145	INJECTION	297 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1145	INJECTION	297 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1147	INJECTION	340 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1147	INJECTION	340 mg	INTRAVENOUS	NDA	20 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

sodium acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: